Willingness to Pay for Cancer Prevention Versus Treatment in China: Implications for Cost-Effectiveness Threshold.

Zixuan Zhao,Yi Yang,Weijia Wu,Hengjin Dong
DOI: https://doi.org/10.1080/14737167.2023.2262141
2023-01-01
Expert Review of Pharmacoeconomics & Outcomes Research
Abstract:BACKGROUND:Empirical support for the appropriate cost-effectiveness threshold (CET) in China remains sparse.OBJECTIVE:This study aimed to estimate the willingness to pay (WTP) for cancer prevention and treatment from the perspective of healthcare policy-makers (i.e. supply side) and to investigate whether there is a difference between the estimated WTP in two scenarios.METHODS:We conducted a web-based survey from May to July 2022 among experts who offering consultation to the government. We surveyed 79 experts from a national think-tank (84.81% response rate) using contingent valuation method, a method for estimating the monetary value that individuals place on a non-market service.RESULTS:The mean WTP for two scenarios were estimated at 1.29 times of per capita Gross Domestic Product (GDP) of China and 1.90 times of per capita GDP, respectively. There was a difference between the WTP in the two scenarios and the WTP for treatment was significantly higher than prevention.CONCLUSION:The findings suggest that though there is a smaller gap between the two scenarios in China as compared to other countries, the WTP may vary under different scenarios. So there's a need to further refine the development of CET by adding parameters like prevention instead of defining one universal threshold.
What problem does this paper attempt to address?